| HLADQA1*05 genotype predicts anti‐drug antibody formation and loss of response during infliximab therapy for inflammatory bowel disease A Wilson, C Peel, Q Wang, AD Pananos, RB Kim Alimentary pharmacology & therapeutics 51 (3), 356-363, 2020 | 70 | 2020 |
| Critical dynamics in population vaccinating behavior AD Pananos, TM Bury, C Wang, J Schonfeld, SP Mohanty, B Nyhan, ... Proceedings of the National Academy of Sciences 114 (52), 13762-13767, 2017 | 68 | 2017 |
| Drug interactions and pharmacogenetic factors contribute to variation in apixaban concentration in atrial fibrillation patients in routine care M Gulilat, D Keller, B Linton, AD Pananos, D Lizotte, GK Dresser, J Alfonsi, ... Journal of Thrombosis and Thrombolysis 49, 294-303, 2020 | 48 | 2020 |
| A Toolbox for Rapid Quantitative Assessment of Chronological Lifespan and Survival in Saccharomyces cerevisiae SR Chadwick, AD Pananos, SE Di Gregorio, AE Park, P Etedali‐Zadeh, ... Traffic 17 (6), 689-703, 2016 | 20 | 2016 |
| The kinetics of regeneration of rhodopsin under enzyme-limited availability of 11-cis retinoid TD Lamb, RM Corless, AD Pananos Vision research 110, 23-33, 2015 | 16 | 2015 |
| A Bayesian approach to estimating the population prevalence of mood and anxiety disorders using multiple measures J Edwards, AD Pananos, A Thind, S Stranges, M Chiu, KK Anderson Epidemiology and psychiatric sciences 30, e4, 2021 | 7 | 2021 |
| Review your choices: when confirmation pages break ballot secrecy in online elections J Brunet, AD Pananos, A Essex International Joint Conference on Electronic Voting, 36-52, 2022 | 4 | 2022 |
| Comparisons between Hamiltonian Monte Carlo and maximum a posteriori for a Bayesian model for Apixaban induction dose & dose personalization AD Pananos, DJ Lizotte Machine Learning for Healthcare Conference, 397-417, 2020 | 4 | 2020 |
| Bayesian Pharmacokinetic Models for Inference and Optimal Sequential Decision Making with Applications in Personalized Medicine AD Pananos The University of Western Ontario (Canada), 2022 | | 2022 |
| immunogenicity of infliximab—ready for routine prediction? Authors' reply A Wilson, C Peel, Q Wang, AD Pananos, RB Kim | | 2020 |
Thomas M. BuryPostdoctoral researcher at McGill UniversityVerified email at mcgill.ca
